Moderna MRNA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 178.2%-32.0pp | 210.2%+0.6pp | 209.6%-19.2pp | 228.8%+19.5pp | 209.4%+31.7pp | |
| Operating margin | -573%-36.0pp | -537%-36.2pp | -500.8%-102pp | -398.7%-14.4pp | -384.3%-17.5pp | |
| Net margin | -522.6%-37.9pp | -484.8%-35.1pp | -449.6%-91.6pp | -358.1%+26.2pp | -384.2%+14.4pp | |
| Returns | ||||||
| Return on equity | -122.2%-7.2pp | -115%-0.1pp | -114.9%-10.1pp | -104.8%+15.0pp | -119.8%+9.7pp | |
| Return on invested capital | -145.8%-7.4pp | -138.4%+0.1pp | -138.5%-10.9pp | -127.7%+3.4pp | -131.1%+0.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×-0.1× | 0.8×-0.1× | 0.9×0.0× | 1×0.0× | |
| Liquidity | ||||||
| Current ratio | 13.6×-1.8× | 15.4×-0.4× | 15.7×-0.5× | 16.2×-0.2× | 16.4×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.5×+0.1× | 0.4×+0.1× | 0.3×0.0× | 0.3×0.0× | 0.4×0.0× | |
| Per Share | ||||||
| Book value per share | $89.14-7.6% | $96.46-6.0% | $102.61-5.5% | $108.58-5.5% | $114.86-6.1% | |
| Valuation | ||||||
| Market capitalization | $52.08B+21.4% | $42.9B-9.5% | $47.38B-24.8% | $63.02B-35.8% | $98.16B-23.3% | |
| Price / sales | 22.9×+5.6× | 17.2×+1.0× | 16.3×-0.6× | 16.8×-5.6× | 22.5×-4.5× | |
| Price / book | 6.2×+1.6× | 4.6×-0.1× | 4.7×-1.1× | 5.8×-2.8× | 8.6×-2.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Moderna's profit margins?
- Moderna (MRNA) runs a 22.1% gross margin and a -153.3% operating margin, with a -143.6% net margin.
- Where do Moderna's ratios come from?
- Every ratio is computed from Moderna's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
